Aptamer Tests Face the Validation Challenge

Clinical adoption will require reproducibility, quality control, and evidence of diagnostic utility

1

Aptamers are short nucleic acid molecules that can bind specific targets, functioning similarly to chemical antibodies.
2

Traditional SELEX for aptamer development is labor-intensive and may yield candidates that perform poorly in complex clinical samples.
3

Newer methods, including microfluidic platforms and AI, aim to enhance aptamer selection speed and performance.
4

Aptamer-based diagnostics require rigorous validation, including assessments of structure, binding strength, and specificity.
5

Despite advantages like chemical synthesis and stability, clinical translation of aptamers remains limited due to performance variability.

1